Nice to know that BPAX has a huge head start in the CV benefits of testosterone, including patent applications. This study is still toying with delivery methods and dosages. At least it is supportive evidence.

Testosterone Supplements May Help Heart Failure Patients

Good point Nutsy, I read the office visit comment but didn't make the connection until you pointed it out.

Generally reverse splits don't work. But that is for companies that are trouble.

You have to ask yourself do you believe in BPAX, their pipeline and management? I do! This wouldn't be an issue if the stock wasn't so heavily manipulated which begs one to wonder if this is part of a bigger plan to force a takeover. If so, you know we will not get anywhere near what the company is worth.

What Biosante has encountered, is bad timing, in that the finish of trial and time to analyze the data may go beyond the July 31st. The 10 consecutive days above $1 has to start by the beginning of the 3rd week of July. In order to get a second 180 day extension, it is my understanding that they need to show that they have a plan to bring the Stock above $1.

I believe we are voting on giving them the option to R/S if needed. Not that we want a R/S.

Since management and the board of directors are large shareholders and have considerable options they can exercise. It is also in their best interest to do what it takes to elevate pps without a R/S.

If they can't show that a R/S is on the table we have tied their hands. If they can not show a plan is in place, they may not get the second 180 extension. Then we may de-list August 1st. Something we don't want.

If the companies future plans involve raising large amounts of capital to finance a marketing arm to sell their approved products then the R/S makes total sense as the higher price will allow them to raise more funding and in the end we keep all the profits and no longer rely on royalties agreements. This would be a plan that I fully support.

Though proper shorting (not naked) is legal, it doesn't mean it is a good thing. It is one of the reasons the US is in such a financial mess. The following is a well written article explaining the global repercussions of shorting. The US just went through the housing bubble for which they are still recovering. What if the same happens to the stock markets,take a good look at what is happening in Europe Spain, Greece etc.... US unemployment topped 10% due to the housing crisis what happens when it closes in on 20%.

Biosante is considered a global leader in the Gene Therapy Industry

This report analyzes the Global market for Gene Therapy in US$ Million. Annual estimates and forecasts are provided for the period 2009 through 2017. The report profiles 98 companies including many key and niche players such as AnGes MG, Inc., BioSante Pharmaceuticals, GenVec, Oxford BioMedica, Shenzhen SiBiono GeneTech Co., Ltd., Transgene, and Vical Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

13. FOCUS ON SELECT GLOBAL PLAYERS II-65
AnGes MG, Inc. (Japan) II-65
BioSante Pharmaceuticals (US) II-65
GenVec (US) II-66
Oxford BioMedica (UK) II-67
Shenzhen SiBiono GeneTech Co., Ltd (China) II-67
Transgene (France) II-67
Vical, Inc. (US) II-68

Report outline

It would be nice to see what the report says. Anybody with access feel free to share.

I am hoping they will consider a phase IV trial and let them submit an NDA application and get it to market. Come June they will have enough safety data to make an application for the HSDD (original purpose of the trials) providing the efficacy issue has been resolved. In addition they had agreed to a follow up study for 5 years to assess long term benefits and safety.

If the FDA was willing to let it on the market safety seems to have been addressed and is much less an issue. In the phase IV trial, once Libigel is in the market place in addition to what ever agreement they had for continued monitoring for HSDD just add a series of targets they wish to monitor (i.e., cholesterol, etc..) for CV reduction. This will determine drug use optimization.

This may be overly simplistic but a fairly logical approach.

Had they not given the go ahead to make the NDA submission pending the passing of the next safety review and when the last patient has been enrolled for 1 year. Then a phase III trial would most likely be needed.

Because it can proven to save a significant number of lives the FDA will not want to drag their feet on this discovery. It comes down to risk vs rewards.

Here is a previous post i submitted on CV disease

CV

Two very good reasons to fast track Libigel

In 2008, CVD was the cause of death in 419,730 females. Females represent 51.7% of deaths from CVD.

In 2009, CVD was the first listed diagnosis of 2.9 million females discharged from short-stay hospitals.

What are thee savings by reducing 71% of the 2.9 million short hospital stays that apply to post menopausal women. You got to figure they account for the majority.

I earlier reported that the CV benefit of Libigel targeting postmenopausal women has a potential (non exclusive)market of $50 billion in the US

BPAX Revenue potential

What do you think the potential of this product is for a company with a global sales network? Remember Intrinsa was using a patch, not as efficient as the transdermal technology used in Libigel.

Just something to ponder. I know that any government providing universal health care will see this as a no brainer. Medication vs Admission not a hard sell.

Firstly thanks for the kind words.

When Biosante decides to come out of CV closet this is what they will be trumpeting it is item #0104 in their Patent application.

There were eight adjudicated cardiovascular events determined from this Phase 3 clinical trial after greater than 4,000 woman-years of therapy. A comparison of the observed number of cardiovascular events to the expected rate of cardiovascular events revealed that the number of observed events was only about 29% of those expected, resulting in a 71% reduction in cardiovascular events.

Postmenopausal Patent

With 4000 women-years examined closer to 6000 women years by now, the CV reduction rate should remain close to 71 % regardless of the size of population. This is solid data which the street should eat up.

If you are not convinced that the government wants this to succeed. Consider the financial savings through the reduction of hospital admissions.

Adam has been complicit in more then one scam. The person who wrote this post did a good job of surfacing the warts in the investment community including politicians and Adam.

Avanir attack

The whole idea of shorting a stock is detrimental to growing the economy. It slows or stops innovation and research. And as long as it persists the US will continue to slide in its standard of living. Those who counter that shorting creates liquidity are creating a false liquidity. Lack of liquidity can be addressed by paying more for a stock. Simple as supply an demand.

Forgot to add that the estimate by Piros never factored a phase III trial for the Pill Plus which should start later this year.

Below is the inclusion criteria and the point system they used.

Table I. BLISS inclusion criteria
1. Postmenopausal women at least 50 y of age with a clinical diagnosis of HSDD (DSM-IV)
2. CV disease risk score if =2(adapted from Barett-Connor et al7) using the following point scale:
a. Age, 60 to <70 y (1 point) or =70 y (2 points)
b. Diabetes mellitus (2 points)
c. Peripheral vascular disease with ankle-brachial index <0.6 (2 points)
d. Documented CV disease (myocardial infarction, stroke, hospitalization for unstable angina/acute coronary syndrome, revascularization of the coronary or peripheral circulations) (2 points)
e. Present smoker of at least 10 cigarettes per day (or the equivalent) (1 point)
f. Hypertension—defined as seated systolic blood pressure =150 mm Hg and/or diastolic blood pressure =95 mm Hg and/or taking antihypertensive medications (for treatment of hypertension)—(1 point)
g. Dyslipidemia—low-density lipoprotein >160 mg/dL and/or high-density liproprotein <45 mg/dL with triglycerides >250 mg/dL and/or taking prescribed lipid-lowering medication (1 point)

I noticed family history of heart disease was an omitted criteria, probably out of fairness as the focus of the drug was HSDD

My wife is Congestive Heart failure nurse who often states that regardless of lifestyle choices (i.e, proper diet, exercise, etc..) family history often catches up with you. If you come a from a family with a history of heart disease it will probably get you.

Just a thought, but it would be very interesting if the restoration of testosterone levels to pre-menopausal levels could be proven to counter the family history issue. A future trial tackling that issue could be an amazing discovery for the medical community. This would be one of the carrots I would use to have the FDA support a phase IV trial. Allowing Libigel to move market and using a larger trial group which would be available once marketed.

Interesting article regarding Biosante as a potential takeover target. Though dated Jul. 19, 2011. it contains key info to help in your analysis.

The following is an excerpt referring to Libigel licensing agreement and a potential buyout.

"Simes told Bloomberg that a "very conservative" estimate for a licensing deal would be $100 million plus royalties, or an acquisition of BioSante within $300 to $500 million. Analyst at Rodman & Renshaw Elemer Piros believes the company’s acquisition price could reach $1 billion, contingent on successful Phase III results. To put these numbers into perspective, BioSante’s (BPAX) market cap was $356.62 million as of July 12."

Takeover Target

Firstly, in addressing potential lawsuits over overstated claims regarding Libigel. The statement Simes makes here would be exactly the opposite. He obviously understates the value of a potential buyout. The market cap at the time was higher then his low end figure.

Secondly, analyst Elemer Piros of Rodman & Renshaw estimates the buyout price could reach $1 billion.

Note: Piros' estimated price did not factor the following:
- the importance of the GVAX hold being removed,
- Gvax pancreas phase II trial with Aduro
- Gvax prostate phase I trial results with Ipi (Yervoy)
- that GVAX was nominated as one of top five vaccines.
- Bio-T-Gel was approved by FDA
- Azur and Jazz have merged creating a larger exposure for Elestrin in the US.
- PharmaSwiss was acquired by Valeant creating a larger client base for Elestrin in Isreal.
- the surprise discovery of a 70 % reduction in the risk of cardiovascular events for postmenopausal women using Libigel.

It would be interesting to see what estimate Piros gives as a buyout price for Biosante with the added information.

And go think today I have to cash in three share for a cup of coffee. Even more if I wanted Starbucks.

Accidentally exchanged the trail names, it should read Bloom trial when referring to efficacy and Bliss trial when referring to CV and breast cancer safety.

Another FDA possibility for Libigel drug advancement is discussed the following yahoo thread.

Interesting FDA meeting next week on product development & CVE's

I agree, the scientific community is objective in their assessment and not only are they more knowledgeable, they are privy to the latest research and the quality of the research. I can't say the same about AF as it is obvious that he will only state what supports his or his puppeteer's agenda.

I see I am not the only one that he company is mysteriously quiet on the GVAX nominations. Something must be up.

GVAX nomination

Don't be surprised if the meeting results in a recommendation to submit an NDA application addressing HSDD and CV with the intent of bringing them to market. Along with an agreement to conduct a phase IV trial for drug optimization.

PHASE IV TRIALS: Post-marketing studies to delineate additional information including the drug's risks, benefits, and optimal use.

This trial can further narrow down the intent to treat optimal group for HSDD and examine additional criteria for CV (cholesterol reduction etc..)

Since testosterone is already being used off label, this would seem the most logical course of action.

It appears that adding all naturally post menopausal women to the Bloom safety study was method to help the FDA get the info on the low dose testosterone and didn't originally fit into the plans of Biosante. Even though the placebo effect hammered the Bliss efficacy trials it too seemed to be used as a tool for the FDA getting safety data beyond what the drug was intended to do. Going beyond the Intent to treat population.

Fortunately the Bloom safety trial discovered that low dose testosterone reduces the risk of Cardiovascular events by over 70%.

The FDA meeting will be very interesting, Biosante has gone above and beyond with these trials. I believe the Biosante and FDA agreement will be highly favorable to Biosante and this will materialize when they come out of the meetings. If so it will encourage other companies to tackle safety issues on other unmet needs.


The following video supports Biosante working with the FDA to get the data they want.
What is Libigel Video

Reassurances that the FDA wants to help Libigel succeed.

I highly recommend reading the Bliss Safety Trial

If you read the discussion section it shows that Biosante was asked to do a lot outside the scope of a normal trial. Reason is that the FDA want the info on the low dose testosterone.

What happens if they make Biosante walk away. They will not get the 5 year follow up information that they desperately want. This also explains why the Bloom efficacy trails were set up the way they were. I have added an excerpt from the discussion section.

"There are additional aspects of the BLISS study that make it unique among recent women's health studies. First, the study not only is attempting to rule out a preapproval level of risk after an average of 2 years (range, 1-4 years) of treatment but also includes a postapproval commitment to follow participants for a total of 5 years each including a period after the primary regulatory analysis and potential approval. In addition, use of an adaptive design to determine sample size and predictive probability to determine correct enrollment have rarely been used in studies of this nature. Furthermore, the indication for LibiGel will initially be in oophorectomized women, but the study is also enrolling naturally menopausal women to explore the safety of LibiGel in a broader population and is based on agreement with FDA. Finally, the CV composite outcome in the BLISS study is expanded compared with other recent studies of CV safety of noncardiac agents, including venous thromboembolic events, because testosterone is an obligate precursor of estradiol, a molecule that can be thrombogenic."

The FDA knows that it has asked a lot. If they aren't going help, no one will ever put themselves out there in the future and stick to the normal clinical trial standards, which overall puts the public at risk.

Though Biosante sold it's US royalty rights for Elestrin. Jazz is getting recognized for their internet marketing strategy of Elestrin. We could see milestone payments yet (up to $140 million if it takes off)

Elestrin Web awards

Elestrin site


According to Chimera Research group, NDA filed for Israel 6/09 by PharmaSwiss (company to be acquired by Valeant Pharma). 2010 10K: elestrin has been approved in Israel.

Since Elestrin initially in the hands of 2 smaller companies and are now in the hands of Jazz and Valeant larger companies. This should end up creating an increased revenue stream from earlier projections. As I understand it Biosante will still get royalties from Valeant.

There are a number of possible catalyst. The problem is all the positive news hasn't clarified when revenue and how much can be expected. The market has written off Libigel and we have not seen any revenue to speak of. News allowing them properly project future revenues is required. That is where a Libigel NDA allowed for a large projected revenue stream bringing in buyers.

I believe positive PR regarding FDA meeting on Libigel would get us to there. Info on the Teva deal would be nice to allow for projected revenue(ie.Teva will launch generic Bio-t-gel with a date) Any revenue from Teva for approval or side deal with Abbott?

I can't see them holding it down any longer, if the PR makes reference to FDA outlining a path forward for the Libigel targeting cardiovascular disease in menopausal women (this would be huge). Heart Disease is a market of approx. $50 billion. It would pop up to a point where a larger number of serious institutional investors would be buying.

A phase II GVAX trial with BMS. This partnership would give it the legitimacy it needs to get over the hump.

Remember analyst were estimating a 1 year target of $6.00 pps primarily on the back of Libigel. In the meantime GVAX has resurrected and was nominated as one of the 5 best vaccines. If Libigel is revived and the CV benefit is added, the stock is definitely worth a lot more then $6 pps. Investors will be clamoring to get in which will push up the price rapidly.

They may be waiting for guidance by FDA and are cautious before announcing anything.

In all honesty I believe something is going on behind the scenes. Contrary to what many believe this company has a very capable management team and a well experience Board. Especially when you consider the following:

1- The silence on the part of the company regarding 70 % reduction CV. They have two patent applications in relation to it. They also have a patent application for mass production of Libigel. All filled in 2012.

2- They have not said anything about the vaccine nominations for best vaccine and best licensing agreements.

3- A number of larger companies are looking for acquisitions. Ealier this year Bristol Myers Squibb bought Inhibitex for $2.5 billion and a few weeks ago Amylin share holders turned down a $3.5 billion offer from BMS.

4 Since management has a number of shares and options anything they do that impacts share price also impacts them.

For all we know a deal may be in place and the results of the FDA meeting will be used to dictate the price.

Nice read, I agree, if Biosante had cash problems I would be concerned. The right news will be too powerful for any type of short attack.

I agree with Double Die, well written.

In addition to avoiding delisting an R/S could make sense even if we go above a buck.

Hypothetically if Biosante wanted to take a serious run at the NDA application and market Libigel and any future drug products itself. It would require a serious infusion of money to create a marketing department. By elevating the share price above $5 it can attract more serious institutional investors. With this infusion of cash they can bring in the right people and have the marketing department ready to hit the ground running around the time Libigel is approved.

The lawsuits are frivolous ambulance chasers and will not succeed for the following reasons.

- Libigel is still alive and in all likely hood will surpass original estimation in the target audience (CV) benefit.

- Management has not sold a single share since early 2007 and a board member bought shares as late as mid November 2011.

- The claims by management were sound based on independent surveys, the phase I & II clinical trials and scientific results of other approved products (not in US)like Intrinsa.

- The phase III clinical trial was double blinded, so management could not of been aware of the top level results and that placebo effect would be that drastic.

- Biosante's forward looking statement indicates that there is no guarantees.

- Investors, those who have done their research and didn't sell as a knee jerk reaction still own their shares and have accumulated more, seeing this as an opportunity.

- You will notice that even real investment firm analyst had down graded BPAX to a hold (not a sell). When the stock price rises above pre-December levels. Those suing will have contributed to their own losses by selling or having a stop loss in place which triggered the sale.

Nutsyprofessor put a good assessment of what happened this week. Many margin calls got triggered because of the global markets going down.

Margin calls

I still believe this stock is a sleeping giant. And that run up to 2013 gives it lots of time to wake up. There are a number of upcoming catalyst. The one which intrigues me is the CV drug play. I find it hard to believe that they haven't received partnership offers on the CV benefit, yet. News in the biotech community like most communities must travel rather fast.

For all we know something may be in the works. This would explain why they have not trumpeted this discovery. Normally discovering your drug reduces the risk of cardiovascular events by over 70% is not something you usually sit on unless you have a very good reason.

As for the $250 market cap. They already have 2 approved drugs Elestrin marketed to Jazz and Bio-t-gel to be marketed by Teva. What they are waiting on revenue to be generated. Once they show that they are generating revenue. Wall Street Investment firms will jump back in. The next drug they have in the pipeline is Libigel and it was estimated as create a $1 billion type market cap if HSDD was a go. I would say triple that (at least) if the get the CV drug is a go. I haven't even touched the impact of GVAX phase three trial or the Pill plus phase 3 trial.

Nominated for best vaccine licensing deal as well for their agreement with Aduro for Pancreas Cancer and Prostate Cancer Vaccine.

They are not meeting for approval. They are meeting to see how they go forward.

Libigel efficacy trial got hit by super high and unexpected placebo results which created the crash in the price in December. They have been evaluating the subset data to narrow the field as who to the drug should be targeted at. Trial extensions were conducted to verify the safety of withdrawing from Libigel and to see if any info can be used to clarify the HSDD test result from the efficacy trial.

However the restoration of testosterone was to pre-menopausal levels which is great since their is no FDA approved method of Hormone Replacement Therapy for women involving testosterone.

Next there is probably the most important discussion in how do they move forward with the discovery of that post menopausal women who use Libigel reduce the risk of a cardiovascular event by 70 %.

FDA may support their subset analysis for the HSDD purpose. Intrinsa and other similar products targeting HSDD outside the US have also had to view subset analysis to get approval. They may ask for an extended trial. If so, if the next safety review is as good as the previous 8, Biosante (possibly with a partner) can make an New Drug Application. Approval comes at the PDUFA date.

The FDA could suggest they move forward with an NDA application for testosterone replacement and suggest another more focused trial for HSDD.

The discussion on the CV benefit will be very interesting. Since heart disease is the number one cause of death in women (around 5 times more then breast cancer). There will be much interest in creating a path to get this product to market. The question will be will the FDA agree that with over 6000 person years of data supporting the claim. Will the FDA consider this enough to allow an NDA application to treat heart disease. or will they want a further trial focusing of the CV benefits, where they further explore Cholesterol reduction etc.... It is a bit of a double edge sword, the longer they wait to allow this to get to market the more women will die on the other hand Vioxx was allowed into market prematurely and caused some deaths. Since the FDA considered the sample size okay for HSDD and if everything went as planned were expected to approve Libigel for HSDD. It should be reasonable to expect that the size would be good enough for a CV drug. After all, the Libigel safety trial was designed to assess the safety of Libigel in relation to Cardiovascular events and Breast Cancer.

In any of these cases they may allow the request a phase IV trial which would allow an NDA submission and they could conduct a larger trial on the product that is marketed. Where they can find additional benefits and clearly define the optimal user group

So basically the meeting is all about how to best move forward. There are many options at their disposal. Libigel will become a product most likely in 2013, early or late will depend on the out come of the meetings.

Another good discussion thread on yahoo as to why Libigel eventually becomes an FDA approved drug. What type of drug is the billion dollar question.

Yahoo thread

Biosante is a recognized leader in nanobiotechnology and gene therapy. Both growing fields, the future looks very bright.

Global Industry Analysts has released a new research report titled ‘Nanobiotechnology: A Global Strategic Business Report.’

Nanobiotechnology

According to the report, the global nanobiotechnology market is expected to achieve a value of $6 billion in 2017

Global Gene Therapy Market to Reach US$794 Million by 2017, According to New Report by Global Industry Analysts, Inc.

Gene Therapy

Authors of the Clinical Trials outcome include;

Talya Waldman, WHNP-BC, NCMP
Women’s Health Nurse Practitioner at the Women’s Heart Center's Advanced Preventive Women’s Clinic. Cedars-Sinai Medical Center

Chrisandra Shufelt MD MS NCMP
Assistant Director, Women's Heart Center, Cedars-Sinai Medical Center

Glenn D. Braunstein, MD
Chairman, Department of Medicine at Cedars-Sinai Medical Center

I am most interested if Shufelf validates the cardiovascular benefit of 71% reduction in cardiovascular events.

Biosante presenting at Future Leaders in the Biotech Industry April 20, 2012

Benefits for Presenting Companies
- Conference marketing focused on highly quali?ed ?nancial professionals, including buyside, sellside and banking institutions
- Targeted marketing to key business development professionals in pharma and big biotech
- High-level sponsors validate conference value
- Full 25-minute presentation to investors followed by 30-minute breakout session
- Opportunity to webcast presentation to reach additional audiences
- Private meeting space available without additional charge
- Designated Presenting Company table at Networking Luncheon
- Full company pro?le from BCIQ: BioCentury Online Intelligence™ available to all registrants
- Company logo posted on of?cial 2012 Future Leaders website for one year after event

Conference Info

Schedule

Biosante has experience creating companies and finding buyers. I am not suggesting they sell Biosante. But if they do, they will ensure the offer reflects the true value of the company, not the manipulated price we are seeing.

Stephen A. Sherwin who sit on Biosante's Board of Directors

He was the co-founder of Abgenix which spun off from Cell Genesys
In 2005 Abgenix was sold to AMGEN for $2.2 billion

Abgenix Sale

Sherwin was on the Abgenix's board at the time of the sale.


Stephen M. Simes (Vice-Chairman, President and Chief Executive Officer)

From 1989 to 1993, Mr. Simes was Chairman, President and Chief Executive Officer of Gynex Pharmaceuticals, Inc., a company which concentrated on the AIDS, endocrinology, urology and growth disorders markets. In 1993, Gynex was acquired by Savient Pharmaceuticals Inc. (formerly Bio-Technology General Corp.)

Forgot to mention they are sitting on Approx $50 million in cash. Enough to take them to late 2013.

Possible reason for today's activity. I do not have access to the Future Science website. But this article was posted today.

Review: Clinical Trial Outcomes

PR may be imminent. Could it be the last chance for MMs to accumulate?

In a nut shell Biosante's lead product Libigel had top level results hit with the placebo effect. Go to the Biosante website and read up on press releases from December 15th, 2011.

Then read the following posts

Pipeline


Potential revenue


Good disussion threads start with Why libigel will be approved it will give context to the FDA meetings

Discussion thread

This should give you a good overview.

Some of the info being discussed at the FDA meeting

Sec. 312.47 Meetings.

(2)"Pre-NDA" and "pre-BLA" meetings. FDA has found that delays associated with the initial review of a marketing application may be reduced by exchanges of information about a proposed marketing application. The primary purpose of this kind of exchange is to uncover any major unresolved problems, to identify those studies that the sponsor is relying on as adequate and well-controlled to establish the drug's effectiveness, to identify the status of ongoing or needed studies adequate to assess pediatric safety and effectiveness, to acquaint FDA reviewers with the general information to be submitted in the marketing application (including technical information), to discuss appropriate methods for statistical analysis of the data, and to discuss the best approach to the presentation and formatting of data in the marketing application. Arrangements for such a meeting are to be initiated by the sponsor with the division responsible for review of the IND. To permit FDA to provide the sponsor with the most useful advice on preparing a marketing application, the sponsor should submit to FDA's reviewing division at least 1 month in advance of the meeting the following information:

Meeting regulations

These meetings meetings should be scheduled to occur within 60 days of FDA receipt of the written meeting request.

If the meeting hasn't already happened it must be getting close.

You are correct on that. Their spread in bid / ask in some trades is down to 1/10,000 of a cent. Soon enough they will realize the accumulation game is over.

Ross J. Mangano (Biosante Director)

Ross Mangano was elected a director of our company in 1999. Mr. Mangano has been the President and a director of Oliver Estate, Inc., a management company specializing in investments in public and private companies, since 1971. He serves on the board of directors of several private companies and U.S. RealTel Inc.


According to filings since 2005 he bought 433,600 shares (and not at December discount prices) His average price is approx.$2.45. He never sold any shares, even when Biosante was trading at $7.33 on May 11, 2007. Obviously he knows the true value of the company (and not the manipulated market cap).

Ross J. Mangano Trades

It is out of our control unless you sell into the MMs accumulation that has been in progress for a couple of months. If in doubt just look the ask and bid activity. When they knock it down fractions of a cent you know that it is not the regular investor or trader. It is computerized trading walking the price down.

Yes, you can make money day trading this stock, but you have to be on the ball and have the time to monitor it. In the long term this stock is best suited as an investment and with patience will turn this stock into a cornerstone of your retirement plan if you let it.

If any one wants to play with it you don't want play with it too long. If you are on the outside looking you may have made profit but will have to give them up and then some in order to get back in, if you can.

As for shorting, well that is a game of financial roulette.

BPAX is one of the most manipulated stock I have ever seen. It is for this reason that it is not where it should be. Once they start showing revenues, or news that Libigel is not only back on track but further ahead and moving towards NDA submission (ie, partner or go it alone) the manipulation will be harder to contain. Based on price projections prior to the December collapse in share price,expect $4 to $6 per share if FDA meetings result in guidance to go forward with Libigel for HSDD and the next safety review is consistent with the last 8 reviews. If a favorable path for the cardiovascular benefit of Libigel comes out of the FDA meeting and the info is released the share price could be in the $10 to $12 range if not higher.

Well said Doctah, one slight correction the reduction in the risk of Cardiovascular events was 71%(much more then slight) and if I am not mistaken the breast cancer rate was on par with the population of the placebo group.